Key research themes
1. How do different DNA damage types and repair pathways interplay to maintain genomic stability and influence cancer therapeutics?
This theme focuses on the classification of DNA damage types (base modifications, single-strand breaks, double-strand breaks, complex lesions, and replication stress-induced structural abnormalities), the corresponding repair pathways (base excision repair, nucleotide excision repair, homologous recombination, non-homologous end joining, mismatch repair, and alternative pathways), and their implications for cancer development and therapy. It addresses how the fidelity, timing, and choice of repair pathways influence mutagenesis, genomic instability, and therapeutic strategies that exploit DNA repair deficiencies.
2. What are the mechanistic characteristics and biological consequences of complex DNA damage induced by ionizing radiation and oxidative stress?
This theme investigates how complex DNA damage, characterized by clustered lesions such as double-strand breaks (DSBs) combined with nearby base lesions or strand breaks, arises predominantly from ionizing radiation and reactive oxygen/nitrogen species. It explores how such clustered lesions differ from isolated damage in repair difficulty, mutation risk, and contribution to genomic instability, carcinogenesis, and therapy resistance. The theme also includes the challenges in detection and measurement of complex damage and its repair kinetics in cell systems.
3. How does the crosstalk between DNA damage response (DDR) and the immune system influence cellular outcomes and cancer therapy?
This theme focuses on the interplay between the cellular DNA damage response and immune signaling pathways, including innate and adaptive immunity. It explores mechanisms by which DNA damage activates immune sensors such as cGAS-STING via micronuclei formation and cytoplasmic DNA, the role of DDR factors in modulating immune responses to infection, inflammation, and cancer, and the therapeutic implications of this interaction in enhancing cancer immunotherapy and mitigating immunological diseases.